drugset
drugset / Trial / NCT04644315

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

NCT04644315 ↗

Phase 2 Terminated 1 enrolled Hoffmann-La Roche
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.

Timeline

Start
2021-05-24
Primary completion
2022-05-16
Completion
2022-05-16

Outcome

Outcome not reported

Stopped: “The data from this study is no longer needed.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Alectinib Small molecule 600 mg Oral

Indications

anaplastic large cell lymphoma brain neoplasm bronchogenic carcinoma cholangiocarcinoma colorectal neoplasm melanoma neuroendocrine neoplasm ovarian neoplasm pancreatic neoplasm sarcoma thyroid gland papillary carcinoma tumor of salivary gland